Real-world Studies of Ocriplasmin
Kim and colleagues reported on their real-world experience with ocriplasmin at a large academic center in a retrospective review with a mean follow-up of 56 days (range, 6 to 133 d). Nineteen patients with symptomatic VMA received intravitreal ocriplasmin; 8 patients (42%) had resolution of their VMA. Macular holes in 3 of 6 patients (50%) closed after injection. Visual acuity improvement was modest with 8/19 patients showing no change in baseline vision, 8/19 patients gaining <2 Early Treatment Diabetic Retinopathy Study lines, and only 2/19 patients gaining 3 or more Early Treatment Diabetic Retinopathy Study lines; these 2 patients had closure of full-thickness macular holes. Factors that were associated with a higher rate of VMA resolution included age below 65 years, focal adhesions ≤1500 μm in breadth, presence of macular hole, phakic status, and absence of epiretinal membrane. There were no cases of postinjection uveitis, endophthalmitis, retinal tears, or detachment throughout the study period.